Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Oct-Dec;18(4):459-63.
doi: 10.4103/0972-2327.165482.

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis

Awadh Kishor Pandit  1 , Kameshwar Prasad  1 , Tulika Seth  2
Affiliations
Case Reports

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis

Awadh Kishor Pandit et al. Ann Indian Acad Neurol. 2015 Oct-Dec.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of central nervous system (CNS), which is disabling and majorly involves younger population. Various available treatments in forms of immunomodulation are not very effective; however, stem cell transplantation seems to be promising in recent literature. The current case report is a novel evidence for autologous hematopoietic stem cell transplantation (HSCT) in progressive MS.

Case summary: A 33 year old male with secondary progressive MS (SPMS), after being failed and/or intolerance to standard approved interferon (IFN) and mitoxantrone therapy, autologous HSCT was administered. At 2years of post-stem cell transplantation follow-up, he has remained stable with some improvement in functional status (Expanded Disability Status Scale (EDSS) reduced by 1.5), with no relapse, no treatment related complications, and no fresh magnetic resonance imaging (MRI) lesions.

Conclusion: Autologous stem cell transplantation may be beneficial in progressive forms of MS, but needs to be tested in well-designed randomized trial.

Keywords: Autologous hematopoietic stem cell transplantation; HSCT in MS; multiple sclerosis; stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Multiple T2-weighted (T2W) and fluid-attenuated inversion recovery (FLAIR) hyperintensity (demylination plaques) noted in periventricular, subcortical, callosal, and spinal cord regions with no progression or fresh lesion in year 2014 images as compared to pre-stem cell transplantation images in year 2012 including the contrast enhanced magnetic resonance imaging (MRI) scans (a-e)
See this image and copyright information in PMC

References

    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–52. - PubMed
    1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain. 2006;129:606–16. - PubMed
    1. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain J Neurol. 1999;122:1941–50. - PubMed
    1. Silani V, Cova L. Stem cell transplantation in multiple sclerosis: Safety and ethics. J Neurol Sci. 2008;265:116–21. - PubMed
    1. Mahevas M, Vaida I, Le Page L, Sid-Idris S, Royer B, Garedi R, et al. Haematopoietic stem cell transplantation in the treatment of autoimmune diseases. Rev Méd Interne. 2008;29:115–21. - PubMed

Publication types